GLP-1

News

Novo Nordisk has latched onto a real-world study that found its weight-loss drug Wegovy works better than Eli Lilly's fast-growing rival Zepbound.

News

Lilly has paused shipments of weight loss therapy Mounjaro to the UK to prevent stockpiling ahead of a price rise, but patients report shortages.

News

Add a beneficial impact on climate change to the long list of benefits being attributed to GLP-1 agonist medicines.

News

New guidelines on NHS management of type 2 diabetes will introduce a more personalised approach that could see expanded access to drug treatments.

News

Viking Therapeutics shares slumped on discontinuation rates with its oral obesity drug in a phase 2 trial, but are investors missing the point?

News

Novo Nordisk has said it will offer diabetes therapy Ozempic at $499 per month for cash-paying customers in the US.